TY - JOUR
T1 - Use of liposomal amphotericin B in critically ill patients: A retrospective, multicenter, clinical study
AU - Álvarez-Lerma, Francisco
AU - Mariscal, F.
AU - Quintana, E.
AU - Rialp, G.
AU - Díaz-Regañón, J.
AU - Pérez, M. J.
AU - Álvarez-Sánchez, B.
AU - Ausín Aoiz, I.
PY - 2009/1/1
Y1 - 2009/1/1
N2 - The clinical use of liposomal amphotericin B in 179 patients admitted to 30 medical-surgical Intensive Care Units (ICUs) treated with this agent in 2006 was analyzed. Invasive fungal infections were proven, probable and possible in 44%, 16%, and 25% of cases, respectively. Fungi isolated were Candida albicans (38%), non-albicans Candida spp. (15%) and Aspergillus spp. (7%). The mean duration of treatment was 15 days (mean dose 3.7 mg/kg/day). The drug was used as rescue treatment after fluconazole or caspofungin in 47% of patients and as firstline in 52% with a satisfactory clinical response in 54% of cases (72.6% with proven infection). Microbiological eradication was achieved in 68% of cases. Adverse events occurred in 51 patients but were severe in only 4. The use of liposomal amphotericin B both as firstline and rescue treatment and mainly for proven invasive fungal infection was associated with a high rate of satisfactory clinical response. © E.S.I.F.T. srl.
AB - The clinical use of liposomal amphotericin B in 179 patients admitted to 30 medical-surgical Intensive Care Units (ICUs) treated with this agent in 2006 was analyzed. Invasive fungal infections were proven, probable and possible in 44%, 16%, and 25% of cases, respectively. Fungi isolated were Candida albicans (38%), non-albicans Candida spp. (15%) and Aspergillus spp. (7%). The mean duration of treatment was 15 days (mean dose 3.7 mg/kg/day). The drug was used as rescue treatment after fluconazole or caspofungin in 47% of patients and as firstline in 52% with a satisfactory clinical response in 54% of cases (72.6% with proven infection). Microbiological eradication was achieved in 68% of cases. Adverse events occurred in 51 patients but were severe in only 4. The use of liposomal amphotericin B both as firstline and rescue treatment and mainly for proven invasive fungal infection was associated with a high rate of satisfactory clinical response. © E.S.I.F.T. srl.
KW - Critically ill patient
KW - ICU
KW - Invasive fungal infections
KW - Liposomal amphotericin B
U2 - 10.1179/joc.2009.21.3.330
DO - 10.1179/joc.2009.21.3.330
M3 - Article
VL - 21
SP - 330
EP - 337
IS - 3
ER -